UK Stem Cell IPOs Defy Odds

 
• By Melanie Senior

When ReNeuron Ltd. announced its intention to float on London's Alternative Investment Market (AIM) in July, most onlookers gave a sceptical laugh. But the subsequent IPO, although small, showed that even risky, pre-clinical bets can float--if they're priced low enough.

When ReNeuron Group PLC announced its intention to float on London's Alternative Investment Market (AIM) in July, most onlookers gave a skeptical laugh. Even the healthiest biotechs, crammed with late-stage programs, have struggled to go public in Europe. (See "Trade Sales Trump IPOs, Even For Platforms," Start-Up, September2005Also see "Trade Sales Trump IPOs, Even for Platforms" - Scrip, 1 September, 2005..) There was no way a firm working on stem cells—a risky, poorly-understood field fraught with ethical concerns—with no clinical programs, was going to make it. Particularly as ReNeuron had tried its luck on the public markets before, in 2000, only to be whisked back into the private realm by its lead VC Merlin Biosciences Ltd. three years later, leaving most investors out of pocket. [See Deal] (See "ReNeuron: Going Private," In Vivo Europe Rx, May 2003 Also see "ReNeuron: Going Private" - In Vivo, 1 May, 2003..)

But ReNeuron defied the skeptics on August 5, raising £9.5 million ($17 million) from a dozen or so investors—including some...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

BIO Notebook: Policy Problems, ACIP’s Future, BI Is Popular, Makary On FDA-Industry Ties

 
• By Sarah Karlin-Smith and Mandy Jackson

Highlights from Day Two of the BIO International Convention include BIO officials raising concerns about Trump Administration policies, the future of ACIP, an interview with BI's head of global business development, and FDA Commissioner Martin Makary's view of the FDA-industry relationship.

Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve

 
• By Joseph Haas

Instead of opting in on Phase II-ready PCSK9-targeted VERVE-102, Lilly will buy its partner for up to $1.3bn. Analysts call the deal a bargain for Lilly, but fair to Verve.

BIO Notebook: IPO Window Stays Shut, PRVs Need To Be A Priority, And Focusing On Gene Therapy Safety

 
• By Mandy Jackson and Sarah Karlin-Smith

Highlights from day one of the BIO convention include advice for firms hoping to go public, a call for companies to push the US Congress on rare disease priority review vouchers, and updates on next-generation gene therapies.

Sarepta Market Dynamics For Elevidys Imperiled By Second Patient Death

 
• By Joseph Haas

With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.

More from Business

Sarepta Market Dynamics For Elevidys Imperiled By Second Patient Death

 
• By Joseph Haas

With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.

Supernus Secures Sage With CVR-Supported Deal

 
• By Jessica Merrill

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.